-
Media Release
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients
-
Media Release
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths
-
Media Release
Alcon introduces new AIR OPTIX® plus HydraGlyde monthly replacement contact lenses at the American Academy of Optometry annual meeting
-
Media Release
Novartis partners with prominent US health advocacy organizations to launch first social networking platform for heart failure patients and their loved ones
-
Media Release
Alcon receives US FDA approval for AcrySof® IQ ReSTOR® +3.0D Multifocal Toric intraocular lens for cataract patients
-
Media Release
Novartis out-licenses three COPD products in the US
-
Media Release
Novartis presents results from first global registration trial of CTL019 in pediatric and young adult patients with r/r B-ALL
-
Media Release
Novartis announces first CAR-T cell therapy BLA for pediatric and young adult patients with r/r B-cell ALL granted FDA Priority Review
-
Media Release
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes
-
Media Release
Novartis' Cosentyx® shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
-
Media Release
Novartis receives FDA approval for first-of-its-kind Kisqali® Femara® Co-Pack for initial treatment of HR+/HER2- advanced or metastatic breast cancer
-
Media Release
Novartis expands global collaboration with Amgen to commercialize first-in-class AMG 334 (erenumab) program in migraine prevention in the U.S. and Canada